Trevi Therapeutics (TRVI) said Monday a phase 2a trial of its investigational drug Haduvio met the primary endpoint of a statistically significant reduction in 24-hour cough frequency in patients with refractory chronic cough.
The company said Haduvio, or oral nalbuphine ER, achieved a reduction in 24-hour cough count of 67% from baseline and 57% on a placebo-adjusted basis at day 21.
Trevi said it plans to discuss the next steps with the US Food and Drug Administration and expects to initiate the next study after receiving the regulator's feedback.
Shares of the company rose more than 32% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。